Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
LBPH - Longboard Pharmaceuticals, Inc.
Market Cap 164.23M P/E - EPS this Y 11.30% Ern Qtrly Grth -
Income -64.74M Forward P/E -3.91 EPS next Y -28.30% 50D Avg Chg -3.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 25.00%
Dividend N/A Price/Book 2.28 EPS next 5Y - 52W High Chg -31.00%
Recommedations 1.60 Quick Ratio 20.69 Shares Outstanding 34.29M 52W Low Chg 165.00%
Insider Own 1.31% ROA -24.04% Shares Float 24.82M Beta 1.26
Inst Own 118.83% ROE -36.71% Shares Shorted/Prior 4.03M/4.84M Price 7.15
Gross Margin - Profit Margin - Avg. Volume 115,251 Target Price 65.88
Oper. Margin - Earnings Date Oct 31 Volume 42,249 Change -2.72%
Healthcare | Biotechnology | United States
About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals, Inc. News
12/03/24 Lundbeck acquires all outstanding shares of Longboard Pharma
11/13/24 Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment
11/12/24 Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
11/07/24 Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
10/15/24 Health Care Roundup: Market Talk
10/15/24 Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
10/15/24 Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn
10/14/24 Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record
10/14/24 Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal
10/14/24 Longboard Pharmaceuticals-H. Lundbeck Deal Undervalues Franchise, Truist Says
10/14/24 Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?
10/14/24 Longboard Pharmaceuticals Strikes $2.6 Billion Deal to Be Acquired by Lundbeck
10/14/24 Sector Update: Health Care Stocks Advance Premarket Monday
10/14/24 Denmark's Lundbeck bets on epilepsy drug with $2.6 billion Longboard deal
10/14/24 Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
10/09/24 Longboard Pharmaceuticals Inc (LBPH) Q2 2024 Earnings Call Highlights: Promising Clinical ...
10/04/24 Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
09/27/24 Longboard Pharmaceuticals begins Phase III Dravet syndrome trial
09/26/24 Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
09/20/24 Longboard Stock Soars on FDA Designations for Epilepsy Drug